Outcomes following exposure to lacosamide monotherapy during pregnancy and breastfeeding -- a prospective case series.

Aim of the study. To evaluate the safety of lacosamide (LCM) monotherapy during pregnancy and breastfeeding. Material and methods. Patients taking LCM monotherapy treated at the university epilepsy clinic were prospectively followed up during pregnancy, delivery, and breastfeeding. Data on seizure frequency, LCM dosage, pregnancy course, delivery and breastfeeding, birth outcome, congenital malformation, and development of newborns was collected. Material and methods. Patients taking LCM monotherapy treated at the university epilepsy clinic were prospectively followed up during pregnancy, delivery, and breastfeeding. Data on seizure frequency, LCM dosage, pregnancy course, delivery and breastfeeding, birth outcome, congenital malformation, and development of newborns was collected. Conclusions and clinical implications. This case series adds to a growing body of evidence suggesting the relative safety of LCM monotherapy throughout pregnancy and breastfeeding. [ABSTRACT FROM AUTHOR]